Dual antiplatelet therapy in patients at high bleeding risk: less is more—more or less-Reference-Cited by-同舟云学术

Dual antiplatelet therapy in patients at high bleeding risk: less is more—more or less

Published:2022-12-14 Issue:11 Volume:44 Page:969-971
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Capodanno Davide¹^ORCID,Greco Antonio¹^ORCID

Affiliation:

1. Azienda Ospedaliero-Universitaria Policlinico ‘G. Rodolico—San Marco’, University of Catania , Via Santa Sofia 78, 95100 Catania , Italy

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

https://academic.oup.com/eurheartj/article-pdf/44/11/969/49519995/ehac713.pdf

Reference11 articles.

1. Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey;Cao;Eur Heart J,2021

2. Antiplatelet therapy after percutaneous coronary intervention;Angiolillo;EuroIntervention,2022

3. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes;Knuuti;Eur Heart J,2020

4. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation;Collet;Eur Heart J,2021

5. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials;Costa;Eur Heart J,2023

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Never too soon to start cardiovascular prevention: the earlier the better;European Heart Journal;2024-09-01

2. Future of factor XI inhibitors in cardiovascular practice;Minerva Cardiology and Angiology;2024-05

3. Periprocedural myocardial infarction and injury;European Heart Journal: Acute Cardiovascular Care;2024-02-07

4. Higher post procedural bleeding in patients with advanced chronic kidney disease undergoing percutaneous coronary intervention;American Journal of Blood Research;2024

5. Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management;Expert Opinion on Drug Safety;2023-12-02